2.57
-0.13(-4.81%)
Currency In USD
| Previous Close | 2.7 |
| Open | 2.67 |
| Day High | 2.7 |
| Day Low | 2.53 |
| 52-Week High | 16.55 |
| 52-Week Low | 1.6 |
| Volume | 586,121 |
| Average Volume | 749,346 |
| Market Cap | 190.77M |
| PE | -2.09 |
| EPS | -1.23 |
| Moving Average 50 Days | 2.29 |
| Moving Average 200 Days | 6.42 |
| Change | -0.13 |
If you invested $1000 in Perspective Therapeutics, Inc. (CATX) 10 years ago, it would be worth $152.98 as of June 01, 2025 at a share price of $2.57. Whereas If you bought $1000 worth of Perspective Therapeutics, Inc. (CATX) shares 5 years ago, it would be worth $368.19 as of June 01, 2025 at a share price of $2.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
GlobeNewswire Inc.
May 30, 2025 9:21 PM GMT
Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were prese
Perspective Therapeutics to Participate in Upcoming May Investor Conferences
GlobeNewswire Inc.
May 01, 2025 11:00 AM GMT
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that memb
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
GlobeNewswire Inc.
Apr 29, 2025 11:00 AM GMT
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that t